Short answer
LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on July 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Topline results from Phase 3 NOVA-2 trial of LB-102 in schizophrenia expected sooner than previously scheduled.
LB PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Topline results from Phase 3 NOVA-2 trial of LB-102 in schizophrenia expected sooner than previously scheduled
- Earlier data availability may accelerate regulatory, partnering, or valuation catalysts for LBRX
- Press release exhibit 99.1 contains the revised timing and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 NOVA-2 topline results now expected in first half 2027, ahead of prior second-half 2027 guidance
- Trial targets approximately 460 schizophrenia patients across 25 U.S. sites
- Pre-NDA meeting with FDA planned for second half 2027, contingent on results
- Cash runway expected through second quarter 2029, covering multiple planned clinical readouts
- Upcoming catalysts include bipolar depression Phase 2 data in first quarter 2028 and adjunctive MDD data in first half 2029
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LB PHARMACEUTICALS INC 8-K filings
Get the next LBRX 8-K as it lands
Follow LBRX for push alerts, or ask the research agent what this filing means.